Segment Reporting (Tables)

3 Months Ended

Mar. 31, 2025

Segment Reporting

Schedule of statements of operations for segment including significant segment expenses

In addition to the significant expense categories included within consolidated net loss presented in the Company’s consolidated statements of operations and comprehensive loss, see below for disaggregated amounts that comprise research and development expenses for the three months ended March 31, 2025 and 2024 (in thousands):

	Three Months Ended March 31,
	2025		2024
Revenue:
License revenue	$	17,389	$	—
Total revenue		17,389		—
Operating expenses:
Research and development expenses
External costs
Clinical Research Organizations, Contract Manufacturing Organizations and clinical trials		65,072		24,264
Professional consulting services		6,403		3,525
Other research and development costs		2,296		1,997
Internal costs
Personnel-related costs		17,659		9,096
Facilities and overhead costs		5,192		3,079
Total research and development expense		96,622		41,961
General and administrative expenses		22,295		5,632
Total operating expenses		118,917		47,593
Loss from operations		(101,528)		(47,593)
Total other income (expense), net		2,565		(2,256)
Consolidated net loss	$	(98,963)	$	(49,849)